Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BMS-986249 |
| Trade Name | |
| Synonyms | BMS986249|BMS986249 |
| Drug Descriptions |
BMS-986249 is a 2nd generation antibody that targets CTLA4, potentially resulting in T-cell activation and increased anti-tumor immune response (AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr LB-B33). |
| DrugClasses | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 |
| CAS Registry Number | NA |
| NCIT ID | C146765 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMS-986249 | BMS-986249 | 0 | 0 |
| BMS-986249 + Nivolumab | BMS-986249 Nivolumab | 0 | 1 |